doi: 10.7326/J23-0089
Social media comparisons can be misleading and discouraging, as everyones progress timeline is different and often slower than online expectations
Efficacy depends on consistent manufacturing, proper storage, and patient adherence
Key takeaways GLP-1 agonists are a class of drugs that were originally designed to treat type 2 diabetes, but their use has expanded to include weight loss, heart and kidney disease risk reduction, and management of obstructive sleep apnea
Common themes in the positive reviews: Reports of "feeling less hungry" though this is consistent with a placebo response, particularly when someone has paid for and is paying close attention to a wellness product
GLP-1, the foundational target shared by all medications in this class, profoundly affects appetite, satiety, and reward